# C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

> **NCT06210243** · PHASE1 · TERMINATED · sponsor: **920th Hospital of Joint Logistics Support Force of People's Liberation Army of China** · enrollment: 2 (actual)

## Conditions studied

- Lymphoma, B-Cell
- CAR-T

## Interventions

- **BIOLOGICAL:** C752

## Key facts

- **NCT ID:** NCT06210243
- **Lead sponsor:** 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-24
- **Primary completion:** 2024-12-24
- **Final completion:** 2024-12-24
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Due to the PI's determination
- **Last updated:** 2025-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06210243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06210243, "C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06210243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*